The ultimate holding company of the firm, Merck KGaA, has announced that it is preparing for strategic options for its consumer health business globally, including full or partial sales of the business as well as strategic partnerships, Merck Ltd said in a BSE filing.
"This strategic initiative would involve the company's consumer health business in India as well," it added.
In India, under its consumer health business, the company sells a broad range of OTC (over-the-counter) products for the treatment of minor ailments.
"The implementation of measure and their specific design are subject to further analysis and decision making by competent bodies" the filing added.
Commenting on the global development, Member of the Executive Board of Merck and CEO Healthcare Belen Garijo said: "We expect increasing internal constraints to fund the business to reach the required scale. Fully anticipating this, we are preparing strategic options."
Merck KGaA has well-recognised brands and products such as Bion, Femibion, Nasivin, Neurobion and Seven Seas in its Consumer Health product portfolio.
Disclaimer: No Business Standard Journalist was involved in creation of this content
